Clinical Trial Search

Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…

Primary: Percent Coefficient of Fat Absorption (CFA%) — 88.28; 62.76 percent CFA — p=<0.001

Primary: Percentage of Participants Who Were Responders After 1 Week of Treatment With Study Medication — 68.4 percentage of participants

Primary: Mean Change in Total Symptom Score (TSS) From Day 1 (Baseline) to Days 8, 15, 29, and 85 — 0.0012; 0.0480; 0.1506; 0.0791 score on a scale

Primary: Improvement in Glucose Regulation — 34.42; 34.42; 35.44; 39.03 ng*hr/mL — p=0.43

Primary: Efficacy of MS1819-SD: Coefficient of Fat Absorption (CFA) — 55.6; 86.2 % CFA

Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants

Primary: Coefficient of Fat Absorption (%) — 47.41; 82.81 Percentage — p=<0.001

Primary: Percent Coefficient of Fat Absorption (CFA) — 78.27; 80.35 percent CFA — p=0.4590

Primary: Percent Coefficient of Fat Absorption (CFA) — 88.55; 55.61 Percent CFA — p=<0.0001

Primary: Number of Patients With Adverse Drug Reaction — 1 participants

Primary: Part 1 Coefficient of Fat Absorption (CFA) — 85.53; 84.59 percentage of fat intake absorbed

Primary: Change in the Coefficient of Fat Absorption (COA-fat Percent) — -34.1; -1.5 percentage COA-fat — p=<0.001

Primary: Coefficient of Fat Absorption (CFA) — 71.0; 70.9; 71.8; 75.9 percentage of fat intake

Primary: Change in the Chest X-ray Atelectasis Score — -1; -0.86; -2.18 units on a scale